Selank
Neuropeptide (anxiolytic / nootropic)
Status & caution. Developed and used in Russia; not FDA-approved. Named in the 2026 reclassification discussion but NOT among the 12 peptides FDA advanced to PCAC review; sold grey-market in the US. Most clinical data are Russian and not widely replicated in Western trials.
At a glance
Indications & what it's studied for
Reported anxiolytic and nootropic effects (anxiety, focus) without the dependence profile of benzodiazepines; influences GABA/serotonin systems and BDNF.
Contraindications & cautions
No established Western contraindications; pregnancy data lacking.
Commonly reported dosing
Reported, not recommended. The following describes what appears in research literature and community use. It is not a protocol, and unapproved peptides have no validated human dosing.
Commonly used intranasally in small daily doses; unvalidated outside its country of origin.
Routes of administration
Intranasal spray; subcutaneous in some community use.
Don't combine with
Caution combining with other serotonergic or CNS-active drugs.
Reported to stack with
Often paired with Semax as a cognitive/mood combination.
Note: "stacking" combines multiple agents and multiplies unknowns; popularity of a combination is not evidence of its safety.
What the research actually shows
Russian clinical studies for anxiety; limited independent Western replication.
Before acting on anything here, see Safety & the grey market and how to read a COA.